Current state in the development of candidate therapeutic HPV vaccines

References

• Wakeham K, Kavanagh K. The burden of HPV-associated anogenital cancers. Curr Oncol Rep. 2014;16(9):402.
   PubMed Web of Science ®Google Scholar
• Forman D, de Martel C, Lacey CJ. et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–23.
   PubMed Web of Science ®Google Scholar
• Maxwell JH, Grandis JR, Ferris RL. HPV-associated head and neck cancer: unique features of epidemiology and clinical management. Annu Rev Med. 2015;67:91–101.
   PubMed Web of Science ®Google Scholar
• Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer–systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35(5):747–755.
   PubMed Web of Science ®Google Scholar
• Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines. 2009;8(12):1663–1679.
   PubMed Web of Science ®Google Scholar
• Kash N, Lee MA, Kollipara R, et al. Safety and efficacy data on vaccines and immunization to human papillomavirus. J Clin Med. 2015;4(4):614–633.
   PubMed Web of Science ®Google Scholar
• Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med. 2010;10(50):7–17.
   PubMedGoogle Scholar
• Ma B, Maraj B, Tran NP, et al. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2012;17(4):469–492.
   PubMed Web of Science ®Google Scholar
• Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12(2):186–192.
   PubMed Web of Science ®Google Scholar
• Ghittoni R, Accardi R, Chiocca S, et al. The role of human papillomaviruses in carcinogenesis. Ecancermedicalscience. 2015;9:526.
   PubMed Web of Science ®Google Scholar
• Klaes R, Woerner SM, Ridder R, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 1999;59(24):6132–6136.
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–350.
   PubMed Web of Science ®Google Scholar
• Doorbar J. Model systems of human papillomavirus-associated disease. J Pathol. 2016;238(2):166–179.
   PubMed Web of Science ®Google Scholar
• Arias-Pulido H, Peyton CL, Joste NE, et al. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol. 2006;44(5):1755–1762.
   PubMed Web of Science ®Google Scholar
• Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007;212(4):356–367.
   PubMed Web of Science ®Google Scholar
• Gray E, Pett MR, Ward D, et al. In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis. Cancer Res. 2010;70(10):4081–4091.
   PubMed Web of Science ®Google Scholar
• Yao Y, Huang W, Yang X, et al. HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an in silico approach. Vaccine. 2013;31(18):2289–2294.
   PubMed Web of Science ®Google Scholar
• Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993;23(9):2242–2249.
   PubMed Web of Science ®Google Scholar
• Riemer AB, Keskin DB, Zhang G, et al. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J Biol Chem. 2010;285(38):29608–29622.
   PubMed Web of Science ®Google Scholar
• Kumar A, Hussain S, Yadav IS, et al. Identification of human papillomavirus-16 E6 variation in cervical cancer and their impact on T and B cell epitopes. J Virol Methods. 2015;218:51–58.
   PubMed Web of Science ®Google Scholar
• Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist. 2005;10(7):528–538.
   PubMed Web of Science ®Google Scholar
• Bergot A-S, Kassianos A, Frazer IH, et al. New approaches to immunotherapy for HPV associated cancers. Cancers (Basel). 2011;3(3):3461–3495.
   PubMedGoogle Scholar
• Sewell DA, Pan ZK, Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine. 2008;26(41):5315–5320.
   PubMed Web of Science ®Google Scholar
• Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol. 2004;53(Pt 5):427–433.
   PubMed Web of Science ®Google Scholar
• Cortes-Perez NG, Azevedo V, Alcocer-Gonzalez JM, et al. Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target. 2005;13(2):89–98.
   PubMed Web of Science ®Google Scholar
• Adachi K, Kawana K, Yokoyama T, et al. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine. 2010;28(16):2810–2817.
   PubMed Web of Science ®Google Scholar
• Schnupf P, Portnoy DA. Listeriolysin O: a phagosome-specific lysin. Institut Pasteur [Microbes Infect]. 2007;9(10):1176–1187.
   PubMed Web of Science ®Google Scholar
• Peters C, Paterson Y. Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts. Vaccine. 2003;21(11–12):1187–1194.
   PubMed Web of Science ®Google Scholar
• Chen Z, Ozbun L, Chong N, et al. Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+FoxP3- and CD8+ T cells. Cancer Immunol Res. 2014;2(9):911–922.
   PubMed Web of Science ®Google Scholar
• Darji A, Guzman CA, Gerstel B, et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell. 1997;91(6):765–775.
   PubMed Web of Science ®Google Scholar
• Krul MR, Tijhaar EJ, Kleijne JA, et al. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol Immunothe CII. 1996;43(1):44–48.
   PubMed Web of Science ®Google Scholar
• Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, et al. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother CII. 2007;56(7):997–1007.
   PubMed Web of Science ®Google Scholar
• Liu DW, Tsao YP, Kung JT, et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol. 2000;74(6):2888–2894.
   PubMed Web of Science ®Google Scholar
• Cassetti MC, McElhiney SP, Shahabi V, et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine. 2004;22(3–4):520–527.
   PubMed Web of Science ®Google Scholar
• Hsieh C-J, Kim TW, Hung C-F, et al. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine. 2004;22(29–30):3993–4001.
   PubMed Web of Science ®Google Scholar
• Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 1996;347(9014):1523–1527.
   PubMed Web of Science ®Google Scholar
• Lamikanra A, Pan ZK, Isaacs SN, et al. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol. 2001;75(20):9654–9664.
   PubMed Web of Science ®Google Scholar
• Zurkova K, Babiarova K, Hainz P, et al. The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector. Oncol Rep. 2009;21(5):1335–1343.
   PubMed Web of Science ®Google Scholar
• Baez-Astua A, Herraez-Hernandez E, Garbi N, et al. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses. J Virol. 2005;79(20):12807–12817.
   PubMed Web of Science ®Google Scholar
• Walczak M, Regts J, van Oosterhout AJ, et al. Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system. Antivir Ther. 2011;16(2):207–218.
   PubMed Web of Science ®Google Scholar
• Riezebos-Brilman A, Regts J, Freyschmidt E-J, et al. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther. 2005;12(18):1410–1414.
   PubMed Web of Science ®Google Scholar
• Riezebos-Brilman A, Regts J, Chen M, et al. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. Vaccine. 2009;27(5):701–707.
   PubMed Web of Science ®Google Scholar
• Ip PP, Boerma A, Walczak M, et al. Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines. Gene Ther. 2015;22(7):560–567.
   PubMed Web of Science ®Google Scholar
• Grasso F, Negri DR, Mochi S, et al. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. Journal International du Cancer [Int J Cancer]. 2013;132(2):335–344.
   PubMed Web of Science ®Google Scholar
• Chang C-L, Ma B, Pang X, et al. Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther J Am Soc Gene Ther. 2009;17(8):1365–1372.
   PubMed Web of Science ®Google Scholar
• Ginaldi L, Loreto MF, Corsi MP, et al. Immunosenescence and infectious diseases. Institut Pasteur [Microbes Infect]. 2001;3(10):851–857.
   PubMed Web of Science ®Google Scholar
• Lin K, Doolan K, Hung C-F, et al. Perspectives for preventive and therapeutic HPV vaccines. J Formosan Med Assoc = Taiwan Yi Zhi. 2010;109(1):4–24.
   PubMed Web of Science ®Google Scholar
• Rosales R, Rosales C. Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol. 2014;5(5):1002–1019.
   PubMedGoogle Scholar
• Su J-H, Wu A, Scotney E, et al. Immunotherapy for cervical cancer: research status and clinical potential. Biodrugs Clin Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 2010;24(2):109–129.
   PubMed Web of Science ®Google Scholar
• Hung C-F, Ma B, Monie A, et al. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther. 2008;8(4):421–439.
   PubMed Web of Science ®Google Scholar
• Kim JW, Hung CF, Juang J, et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. 1011-1018;11(12):2004.
   Google Scholar
• Fu TM, Ulmer JB, Caulfield MJ, et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med. 1997;3(6):362–371.
   PubMed Web of Science ®Google Scholar
• Porgador A, Irvine KR, Iwasaki A, et al. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med. 1998;188(6):1075–1082.
   PubMed Web of Science ®Google Scholar
• Chattergoon MA, Robinson TM, Boyer JD, et al. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. J Immunol. 1998;160(12):5707–5718.
   PubMed Web of Science ®Google Scholar
• Dupuis M, Denis-Mize K, Woo C, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol. 2000;165(5):2850–2858.
   PubMed Web of Science ®Google Scholar
• Tsen SW, Paik AH, Hung C-F, et al. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines. 2007;6(2):227–239.
   PubMed Web of Science ®Google Scholar
• Cheng W-F, Hung C-F, Hsu K-F, et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther. 2002;13(4):553–568.
   PubMed Web of Science ®Google Scholar
• Berglund P, Quesada-Rolander M, Putkonen P, et al. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses. 1997;13(17):1487–1495.
   PubMed Web of Science ®Google Scholar
• Hsu KF, Hung CF, Cheng WF, et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. 2001;8(5):376–383.
   PubMed Web of Science ®Google Scholar
• Kim TW, Hung C-F, Juang J, et al. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Ther. 2004;11(3):336–342.
   PubMed Web of Science ®Google Scholar
• Varnavski AN, Young PR, Khromykh AA. Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors. J Virol. 2000;74(9):4394–4403.
   PubMed Web of Science ®Google Scholar
• Herd KA, Harvey T, Khromykh AA, et al. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour. Virology. 2004;319(2):237–248.
   PubMed Web of Science ®Google Scholar
• Sebastian M, Papachristofilou A, Weiss C, et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer. 2014;14:748.
   PubMed Web of Science ®Google Scholar
• Mackova J, Kutinova L, Hainz P, et al. Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12. Int J Oncol. 2004;24(6):1581–1588.
   PubMed Web of Science ®Google Scholar
• Wang TL, Ling M, Shih IM, et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther. 2000;7(9):726–733.
   PubMed Web of Science ®Google Scholar
• Benencia F, Courreges MC, Coukos G. Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med. 2008;6:21.
   PubMed Web of Science ®Google Scholar
• Murakami M, Gurski KJ, Marincola FM, et al. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res. 1999;59(6):1184–1187.
   PubMed Web of Science ®Google Scholar
• Peng S, Kim TW, Lee JH, et al. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther. 2005;16(5):584–593.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kang TH, Noh KH, et al. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunol Lett. 2009;122(1):58–67.
   PubMed Web of Science ®Google Scholar
• Adams M, Navabi H, Jasani B, et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]: poly[C(12)U] (Ampligen R). Vaccine. 2003;21(7–8):787–790.
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Roman JJ, et al. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des. 2005;11(27):3485–3500.
   PubMed Web of Science ®Google Scholar
• Ahn Y-H, Hong S-O, Kim JH, et al. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-beta receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity. Clin Exp Immunol. 2015;181(1):164–178.
   PubMed Web of Science ®Google Scholar
• Mikyskova R, Indrova M, Simova J, et al. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int J Oncol. 2004;24(1):161–167.
   PubMed Web of Science ®Google Scholar
• Chang EY, Chen CH, Ji H, et al. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Journal International du Cancer [Int J Cancer]. 2000;86(5):725–730.
   PubMed Web of Science ®Google Scholar
• Vogel FR. Immunologic adjuvants for modern vaccine formulations. Ann N Y Acad Sci. 1995;754:153–160.
   PubMed Web of Science ®Google Scholar
• Guimaraes LE, Baker B, Perricone C, et al., Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190–209.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov. 2003;2(9):727–735.
   PubMed Web of Science ®Google Scholar
• Cheng WF, Hung CF, Chai CY, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001;108(5):669–678.
   PubMed Web of Science ®Google Scholar
• Yang B, Yang A, Peng S, et al. Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination. Cell Biosci. 2015;5:35.
   PubMed Web of Science ®Google Scholar
• Kim TW, Hung C-F, Zheng M, et al. A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response. J Biomed Sci. 2004;11(4):493–499.
   PubMed Web of Science ®Google Scholar
• Villarreal DO, Wise MC, Siefert RJ, et al. Ubiquitin-like molecule ISG15 acts as an immune adjuvant to enhance antigen-specific CD8 T-cell tumor immunity. Mol Ther J Am Soc Gene Ther. 2015;23:1653–1662.
   PubMed Web of Science ®Google Scholar
• Heidenreich R, Jasny E, Kowalczyk A, et al. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Journal International du Cancer [Int J Cancer]. 2015;137(2):372–384.
   PubMed Web of Science ®Google Scholar
• Chen CH, Wang TL, Hung CF, et al. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine. 2000;18(19):2015–2022.
   PubMed Web of Science ®Google Scholar
• Wlazlo AP, Deng H, Giles-Davis W, et al. DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. Cancer Gene Ther. 2004;11(6):457–464.
   PubMed Web of Science ®Google Scholar
• Rittich S, Duskova M, Mackova J, et al. Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2. Oncol Rep. 2005;13(2):311–317.
   PubMed Web of Science ®Google Scholar
• Lin C-T, Hung C-F, Juang J, et al. Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol Ther J Am Soc Gene Ther. 2003;8(4):559–566.
   PubMed Web of Science ®Google Scholar
• Mackova J, Stasikova J, Kutinova L, et al. Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunol Immunother CII. 2006;55(1):39–46.
   PubMed Web of Science ®Google Scholar
• Yue FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Journal International du Cancer [Int J Cancer]. 1997;71(4):630–637.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 1118-1122;7(10):2001.
   Google Scholar
• Chuang C-M, Hoory T, Monie A, et al. Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine. 2009;27(5):684–689.
   PubMed Web of Science ®Google Scholar
• Rice AE, Latchman YE, Balint JP, et al. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Cancer Gene Ther. 2015;22:454–462.
   PubMed Web of Science ®Google Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7(1):41–51.
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med. 2004;10(1):15–18.
   PubMed Web of Science ®Google Scholar
• Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell. 2004;5(3):241–251.
   PubMed Web of Science ®Google Scholar
• Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734–738.
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K, et al. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66(11):5527–5536.
   PubMed Web of Science ®Google Scholar
• Prasad KN, Kumar B, Yan X-D, et al. Alpha-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. J Am Coll Nutr. 2003;22(2):108–117.
   PubMed Web of Science ®Google Scholar
• Kang TH, Knoff J, Yeh WH, et al. Treatment of tumors with vitamin E suppresses myeloid derived suppressor cells and enhances CD8 + T cell-mediated antitumor effects. Plos One. 2014;9(7):e103562.
   Google Scholar
• Bartkowiak T, Singh S, Yang G, et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A. 2015;112(38):E5290–5299.
   PubMed Web of Science ®Google Scholar
• Lee SY, Huang Z, Kang TH, et al. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8(+) T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. J Mol Med (Berl). 2013;91(10):1221–1231.
   PubMed Web of Science ®Google Scholar
• Soong R-S, Song L, Trieu J, et al. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNgamma. Clin Cancer Res Off J Amer Assoc Cancer Res. 2014;20(21):5456–5467.
   Web of Science ®Google Scholar
• Lee S-J, Song L, Yang M-C, et al. Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation. Vaccine. 2015;33(13):1549–1555.
   PubMed Web of Science ®Google Scholar
• Lu D, Hoory T, Monie A, et al. Treatment with demethylating agent, 5-aza-2ʹ-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine. 2009;27(32):4363–4369.
   PubMed Web of Science ®Google Scholar
• Kang TH, Lee JH, Song CK, et al. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res. 2007;67(2):802–811.
   PubMed Web of Science ®Google Scholar
• Bae SH, Park Y-J, Park J-B, et al. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res Off J Amer Assoc Cancer Res. 2007;13(1):341–349.
   Web of Science ®Google Scholar
• Ye GW, Park J-B, Park Y-J, et al. Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity. Mol Ther J Am Soc Gene Ther. 2007;15(8):1564–1570.
   PubMed Web of Science ®Google Scholar
• Tseng C-W, Monie A, Wu C-Y, et al. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berl). 2008;86(8):899–908.
   PubMed Web of Science ®Google Scholar
• Tseng C-W, Trimble C, Zeng Q, et al. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother CII. 2009;58(5):737–748.
   PubMed Web of Science ®Google Scholar
• Chuang C-M, Monie A, Wu A, et al. Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J Biomed Sci. 2009;16:49.
   PubMed Web of Science ®Google Scholar
• Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol. 2007;30(1):233–245.
   PubMed Web of Science ®Google Scholar
• Tseng CW, Monie A, Trimble C, et al. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine. 2008;26(34):4314–4319.
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Yang L-H, Yang H-Y, et al. Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res Off J Amer Assoc Cancer Res. 2014;20(3):644–657.
   Web of Science ®Google Scholar
• Peng S, Lyford-Pike S, Akpeng B, et al. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother CII. 2013;62(1):171–182.
   PubMed Web of Science ®Google Scholar
• Peng S, Wang JW, Karanam B, et al. Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. Plos One. 2015;10(1):e116389.
   PubMed Web of Science ®Google Scholar
• Lee SY, Kang TH, Knoff J, et al. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunology, Immunotherapy: CII. 2013;62(7):1175–1185.
   PubMed Web of Science ®Google Scholar
• Trimble C, Lin C-T, Hung C-F, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine. 2003;21(25–26):4036–4042.
   PubMed Web of Science ®Google Scholar
• Babiuk LA, van Drunen Littel-van den H, Babiuk SL. Immunization of animals: from DNA to the dinner plate. Vet Immunol Immunopathol. 1999;72(1–2):189–202.
   PubMed Web of Science ®Google Scholar
• Best SR, Peng S, Juang C-M, et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 2009;27(40):5450–5459.
   PubMed Web of Science ®Google Scholar
• Tsen SW, Wu C-Y, Meneshian A, et al. Femtosecond laser treatment enhances DNA transfection efficiency in vivo. J Biomed Sci. 2009;16:36.
   PubMed Web of Science ®Google Scholar
• Klencke B, Matijevic M, Urban RG, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res Off J Amer Assoc Cancer Res. 2002;8(5):1028–1037.
   PubMed Web of Science ®Google Scholar
• Jeanbart L, Ballester M, de Titta A, et al. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res. 2014;2(5):436–447.
   PubMed Web of Science ®Google Scholar
• Sun Y, Peng S, Qiu J, et al. Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors. Gene Ther. 2015;22(7):528–535.
   PubMed Web of Science ®Google Scholar
• Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009;27(30):3975–3983.
   PubMed Web of Science ®Google Scholar
• Kawana K, Adachi K, Kojima S, et al. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. Vaccine. 2014;32(47):6233–6239.
   PubMed Web of Science ®Google Scholar
• Brun J-L, Dalstein V, Leveque J, et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol. 2011;204(2):169 e161–168.
   Web of Science ®Google Scholar
• Corona Gutierrez CM, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther. 2004;15(5):421–431.
   PubMed Web of Science ®Google Scholar
• Albarran YCA, De La Garza A, Cruz Quiroz BJ, et al. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. Biodrugs Clin Immunotherapeutics Biopharmaceuticals Gene Ther. 2007;21(1):47–59.
   PubMed Web of Science ®Google Scholar
• Rosales R, Lopez-Contreras M, Rosales C, et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther. 2014;25(12):1035–1049.
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–1847.
   PubMed Web of Science ®Google Scholar
• De Vos Van Steenwijk PJ, Ramwadhdoebe TH, Lowik MJ, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother CII. 2012;61(9):1485–1492.
   PubMed Web of Science ®Google Scholar
• Van Poelgeest MI, Welters MJ, Van Esch EM, et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med. 2013;11:88.
   PubMed Web of Science ®Google Scholar
• de Vos van Steenwijk PJ, Van Poelgeest MI, Ramwadhdoebe TH, et al. The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study. Cancer Immunol Immunother CII. 2014;63(2):147–160.
   PubMed Web of Science ®Google Scholar
• Zandberg DP, Rollins S, Goloubeva O, et al. A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol Immunother CII. 2015;64(3):367–379.
   PubMed Web of Science ®Google Scholar
• de Jong A, O’Neill T, Khan AY, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine. 2002;20(29–30):3456–3464.
   PubMed Web of Science ®Google Scholar
• Daayana S, Elkord E, Winters U, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer. 2010;102(7):1129–1136.
   PubMed Web of Science ®Google Scholar
• Davidson EJ, Faulkner RL, Sehr P, et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine. 2004;22(21–22):2722–2729.
   PubMed Web of Science ®Google Scholar
• Smyth LJ, Van Poelgeest MI, Davidson EJ, et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res an Off J Amer Assoc Cancer Res. 2004;10(9):2954–2961.
   PubMed Web of Science ®Google Scholar
• Maldonado L, Teague JE, Morrow MP, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med. 2014;6(221):221ra213.
   Web of Science ®Google Scholar
• Kim TJ, Jin HT, Hur SY, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317.
   PubMed Web of Science ®Google Scholar
• Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012;4(155):155ra138.
   PubMed Web of Science ®Google Scholar
• Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–2088.
   Web of Science ®Google Scholar
• Santin AD, Bellone S, Palmieri M, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol. 2008;82(4):1968–1979.
   PubMed Web of Science ®Google Scholar
• Ramanathan P, Ganeshrajah S, Raghanvan RK, et al. Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer–a feasibility study. Asian Pacific J Cancer Prev APJCP. 2014;15(14):5909–5916.
   PubMedGoogle Scholar
• Gunn GR, Zubair A, Peters C, et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167(11):6471–6479.
   PubMed Web of Science ®Google Scholar
• Rosales C, Graham VV, Rosas GA, et al. A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol Immunother CII. 2000;49(7):347–360.
   PubMed Web of Science ®Google Scholar
• Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002;169(1):350–358.
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Kwappenberg KM, O’Neill T, et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine. 2001;19(27):3652–3660.
   PubMed Web of Science ®Google Scholar
• Yan J, Harris K, Khan AS, et al. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine. 2008;26(40):5210–5215.
   PubMed Web of Science ®Google Scholar
• Yan J, Reichenbach DK, Corbitt N, et al. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine. 2009;27(3):431–440.
   PubMed Web of Science ®Google Scholar